Get Sample Brochure of Report @ http://www.marketintelreports.com/pdfdownload.php?id=gdhc3214ctidb Get Sample Brochure of Report @ http://www.marketintelreports.com/pdfdownload.php?id=gdhc3214ctidb The report includes detailed analysis on Melanoma Treatment Market segmentation, global notable vendors, geographical outlook, price & financial updates, segment & application approach and future forecasts.

1. Melanoma Global Clinical Trials Review, H1,
2016
Published on – 31,January, 2016 | Number of pages :NA
Single User Price: $2500
The global treatment market for melanoma will expand more than
fourfold in value from $1.34 billion in 2013 to reach an estimated
$5.64 billion by 2023, representing a robust Compound Annual
Growth Rate (CAGR) of 15.5%, according to MarketIntelReports

2. “Melanoma Global Clinical Trials Review, H1, 2016" provides an overview of
Melanoma clinical trials scenario. This report provides top line data relating to the
clinical trials on Melanoma. Report includes an overview of trial numbers and their
average enrollment in top countries conducted across the globe.
MarketIntelReports latest report states that this impressive growth, which will occur
across the eight major markets (8MM) of the US, France, Germany, Italy, Spain, UK,
Japan, and Australia, will be driven primarily by increasing sales of Bristol-Myers
Squibb's blockbuster immunotherapy Yervoy.
"While Yervoy's sales will be negatively impacted by the first-line uptake of PD-1-
targeting monoclonal antibodies (mAbs) Keytruda and Opdivo from 2015 to 2017, the
approval of the Yervoy/Opdivo combination will recover the former's market position
in the second half of the forecast period.
"Furthermore, Yervoy's label expansion into the lucrative adjuvant setting will further
enhance its sales from 2019 onwards."

3. Click Here To Check Complete Report
Some of the prominent players of market:
Bristol-Myers Squibb Company F. Hoffmann-La Roche Ltd. GlaxoSmithKline Plc
Merck & Co., Inc. Novartis AG AstraZeneca Plc Pfizer Inc. Ludwig Institute For
Cancer Research Ltd Eisai Co., Ltd. Amgen Inc. and Others
The BRAF/MEK inhibitor combinations, in particular Novartis' Tafinlar/Mekinist
and Roche/Exelixis' Zelboraf/cobimetinib, will replace standard BRAF inhibitor
monotherapy of Zelboraf or Tafinlar. In addition, Keytruda and Opdivo will garner
rapid growth in both BRAF mutated and wild-type settings.
"These novel agents and combinations will experience large uptake globally,
thanks to their improved overall response rate and overall survival, along with
their manageable side effect profiles. Notably, the combination treatments will
fetch a higher premium price than monotherapies, which, on top of raising
company sales, will also result in greater pushback from payers."

4. MarketIntelReports expects these new, more efficacious entrants to replace
generic chemotherapy-only regimens in the first- and second-line settings,
therefore driving the growth of the overall melanoma market and extending the
lines of treatment available for patients.
"The launch of these improved agents will ensure that many patients receive one
to two lines of treatment with branded premium-priced drugs by 2023 and
beyond."
Download Sample Brochure

5. Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this
market report. Details are provided within the report.
Make an Inquiry Before Buying

6. Melanoma Global Clinical Trials Review, H1,
2016
A detailed qualitative analysis of the factors responsible for driving and restraining
growth of the Melanoma Global Clinical Trials Review, H1, 2016
and future opportunities are provided in the report.
Contact:
1-302-684-6088
sales@marketintelreports.com
www.marketintelreports.com
Click Here To Order Melanoma
Global Clinical Trials Review, H1,
2016 Market Report

7. Melanoma Global Clinical Trials Review, H1,
2016
A detailed qualitative analysis of the factors responsible for driving and restraining
growth of the Melanoma Global Clinical Trials Review, H1, 2016
and future opportunities are provided in the report.
Contact:
1-302-684-6088
sales@marketintelreports.com
www.marketintelreports.com
Click Here To Order Melanoma
Global Clinical Trials Review, H1,
2016 Market Report